Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MesoblastASX:MSB -5.98%35 Revenue per Share is A$0.00 as of Mar. 2026. GuruFocus rates ASX:MSB with a GF Score™ of 35/100. The stock has 4 warning signs investors should review. Among 768 Biotechnology companies, Mesoblast ranks worse than 52.21% on this metric.
Mesoblast's revenue per share for the
three
months ended in Mar. 2026 was A$0.00.
Mesoblast's revenue per share for the trailing twelve months (TTM) ended in Mar. 2026 was A$0.00.
Warning Sign:
Mesoblast Ltd revenue per share has been in decline for the last 5 years.
During the past 3 years, the average Revenue Per Share Growth Rate was 1.60% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was -21.60% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was -14.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Mesoblast's Revenue per Share or its related term are showing as below:
ASX:MSB'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -62.5 Med: -15.9 Max: 299
Current: 1.6
During the past 13 years, Mesoblast's highest 3-Year average Revenue Per Share Growth Rate was 299.00% per year. The lowest was -62.50% per year. And the median was -15.90% per year.
ASX:MSB's 3-Year Revenue Growth Rate is ranked worse than 52.21% of 768
companies
in the Biotechnology industry
Industry Median: 2.95
vs ASX:MSB: 1.60
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Mesoblast Revenue per Share Related Terms
Mesoblast Revenue per Share Historical Data
* Premium members only.
The historical data trend for Mesoblast's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:MSB vs VRTX, REGN, RVMD: Revenue per Share Comparison
For the Biotechnology subindustry, Mesoblast's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mesoblast PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mesoblast's PS Ratio distribution charts can be found below:
* The bar in red indicates where Mesoblast's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Mesoblast's Revenue Per Share for the fiscal year that ended in Jun. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was A$0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mesoblast (ASX:MSB) has a Revenue per Share of A$0.00 as of Mar. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Mesoblast and its competitors. According to the industry distribution chart, Mesoblast ranks #401 out of 768 companies in the Biotechnology industry, placing it in the top 52.2%.
Is Mesoblast's Revenue per Share too high?
Mesoblast's current Revenue per Share is A$0.00. Based on the distribution chart, Mesoblast ranks #401 out of 768 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Mesoblast has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Mesoblast's Revenue per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Mesoblast ranks #401 out of 768 companies for Revenue per Share. This places Mesoblast in the lower half of its industry. The industry median Revenue per Share is 2.95. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Biotechnology company?
The median Revenue per Share among Biotechnology companies is 2.95, based on 768 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Mesoblast and its competitors. For the Biotechnology industry, the median Revenue per Share is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mesoblast's current Revenue per Share is A$0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mesoblast stock overvalued right now?
Mesoblast (ASX:MSB) has a current Revenue per Share of A$0.00. The current Revenue per Share is A$0.00. Mesoblast's overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Mesoblast (ASX:MSB), the current Revenue per Share is A$0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
35GF Score
Get the complete analysis for ASX:MSB
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MSB has been successfully added to your 
